Evaluation of a novel anti-ischemic agent in acute coronary syndromes: Design and rationale for the Metabolic Efficiency with Ranolazine for Less Ischemia in Non–ST-elevation acute coronary syndromes (MERLIN)-TIMI 36 trial
Authors:
- Benjamin M. SciricaBSBenjamin M. Scirica
- Ewa Karwatowska-ProkopczukEKEwa Karwatowska-Prokopczuk
- Allan SkeneASAllan Skene
- Carolyn H. McCabeCMCarolyn H. McCabe
- Eugene BraunwaldEBEugene Braunwald
- 30 June 2006
- journal article
- research article
- Published by Elsevier in American Heart Journal
- Vol. 151 (6) , 1186.e1-1186.e9
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe anginaJACC, 2004
- Effects of Ranolazine With Atenolol, Amlodipine, or Diltiazem on Exercise Tolerance and Angina Frequency in Patients With Severe Chronic AnginaA Randomized Controlled TrialJAMA, 2004
- Intracellular Na+ regulation in cardiac myocytesCardiovascular Research, 2003
- Defective cardiac ion channels: from mutations to clinical syndromesJournal of Clinical Investigation, 2002
- ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction—summary articleJACC, 2002
- Intracellular Sodium Accumulation During Ischemia as the Substrate for Reperfusion InjuryCirculation Research, 1999
- Sodium Regulation During Ischemia Versus Reperfusion and Its Role in InjuryCirculation Research, 1999
- Ranolazine Stimulates Glucose Oxidation in Normoxic, Ischemic, and Reperfused Ischemic Rat HeartsCirculation, 1996
- Ionic basis of ischaemic cardiac injury: insights from cellular studiesCardiovascular Research, 1994
- A persistent sodium current in rat ventricular myocytes.The Journal of Physiology, 1992